As the prognosis of metastatic non-small cell lung cancer (NSCLC) patients is constantly
improving with advances in systemic therapies (immune checkpoint blockers and new …

Purpose Distinguishing radiation necrosis (RN) from recurrent tumor remains a vexing
clinical problem with important health-care consequences for neuro-oncology patients …

Background Radionecrosis is a common complication in radiation oncology, while
mechanisms and risk factors have yet to be fully explored. We therefore conducted a …

The place of bevacizumab (BEV) in salvage re-irradiation (Re-RT) settings of malignant
glioma is poorly defined. In the current study risk/benefit profiles of two BEV-based Re-RT …

Purpose There is mounting evidence that, in addition to angiogenesis, hypoxia-induced
inflammation via the hypoxia-inducible factor 1α (HIF-1α)–CXC chemokine receptor 4 …

Recurrent malignant gliomas (RMGs) are difficult to control, and no standard protocol has
been established for their treatment. At our institute, we have often treated RMGs by tumor …

Purpose Clinical evidence suggests radiation induces changes in the brain
microenvironment that affect subsequent response to treatment. This study investigates the …

Background Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is a
new treatment approach for radionecrosis. In our study, we compared the prophylactic and …

Anti-vascular endothelial growth factor (anti-VEGF) antibodies are a promising new
treatment for late time-to-onset radiation-induced necrosis (RN). We sought to evaluate and …

Background: With the development of radiological technologies, radiotherapy has been
gradually widely used in the clinic to intracranial tumours and become standardised …